secwatch.observer — SEC 8-K summary
======================================

Issuer:     SELLAS Life Sciences Group, Inc. (SLS)
CIK:        0001390478
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001390478-25-000017
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SELLAS Q2 net loss $0.07/sh; GPS Phase 3 IDMC positive; SLS009 meets endpoints
------------------------------------------------------------------------------

- IDMC recommends continuing pivotal Phase 3 REGAL trial of GPS in AML without modification; final analysis by year-end 2025.
- Phase 2 SLS009 in r/r AML met all primary endpoints: 44% ORR in AML-MRC; median OS 8.9 months vs 2.4 month historical benchmark.
- FDA recommends advancing SLS009 into first-line AML trial; 80-patient enrollment expected by Q1 2026.
- Q2 2025 net loss $6.6M ($0.07/sh) vs $7.5M ($0.13/sh) in Q2 2024.
- Cash $25.3M at June 30, 2025; additional $4.0M from warrant exercises in July 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1390478/000139047825000017/0001390478-25-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1390478/000139047825000017/sls-20250812.htm
  HTML page:      https://secwatch.observer/filing/0001390478-25-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer